Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia

Leukemia

Volumn 26, Issue 4, 2012, Pages 841-844

  Kofler, D M ^a   Gawlik, B B ^a   Elter, T ^a   Gianella Borradori, A ^b   Wendtner, C M ^a,c   Hallek, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MERCK SERONO S A   (Switzerland)

^c Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CYTOTOXIC AGENT; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

APOPTOSIS; AREA UNDER THE CURVE; BRONCHITIS; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CATHETER INFECTION; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG TOLERANCE; EAR INFECTION; FLOW CYTOMETRY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC CORRELATION; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; JOINT SWELLING; LETTER; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LUNG INFILTRATE; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; OSTEOARTHRITIS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RIB FRACTURE; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS INFECTION; SYNOVITIS; TENDON RUPTURE; TREATMENT FAILURE; VIRUS PNEUMONIA;

B-CELL ACTIVATING FACTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84859642220     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.286     Document Type: Letter

References (8)

1. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell through activation of the canonical NF-kappa B pathway survival. Blood 2007; 109: 703-710. (Pubitemid 46105972)
2. Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszyñska A et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 2009; 33: 1319-1327.
3. Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007; 92: 1284-1285. (Pubitemid 350144199)
4. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S et al. Elevated serum B-Lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 24: 983-987. (Pubitemid 46638853)
5. Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S et al. Genetic variants in apoptosis and immunoregulation- related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 2008; 68: 10178-10186.
6. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukaemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997. (Pubitemid 26189840)
7. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007; 67: 9609-9612. (Pubitemid 47621204)
8. Inoue K, Mineharu Y, Inoue S, Yamada S, Matsuda F, Nozaki K et al. Search on chromosome 17 centromere reveals TNFRSF13B as a susceptibility gene for intracranial aneurysm: a preliminary study. Circulation 2006; 113: 2002-2010.